multiple immune-mediated inflammatory diseases
Rheumatology · 2023–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Multiple indications including ankylosing spondylitis, Crohn disease, ulcerative colitis, hidradenitis suppurativa, juvenile idiopathic arthritis, rheumatoid… | Nov 2023 | Recommended with restriction | input received Colitis Australia |
Who spoke
Colitis Australia
What the PBS pays
$242M in government benefit over 2024–25, across 411,820 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| adalimumab | $241.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.